305 related articles for article (PubMed ID: 33284685)
1. Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.
Ann Intern Med; 2021 Mar; 174(3):I16. PubMed ID: 33284685
[No Abstract] [Full Text] [Related]
2. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
[TBL] [Abstract][Full Text] [Related]
3. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
Saudi Med J; 2021 Mar; 42(3):342-343. PubMed ID: 33632915
[No Abstract] [Full Text] [Related]
4. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
5. Has the door closed on hydroxychloroquine for SARS-COV-2?
Paul M
Clin Microbiol Infect; 2021 Jan; 27(1):3-5. PubMed ID: 33096242
[No Abstract] [Full Text] [Related]
6. The Rediscovery of Hydroxychloroquine in Allergic Diseases in the COVID-19 Era.
Bonzano L; Cassone G; Tarallo L; Pellacani G
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):85-86. PubMed ID: 32474406
[No Abstract] [Full Text] [Related]
7. Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.
Agarwal M; Ranjan P; Mittal A; Baitha U
Expert Rev Anti Infect Ther; 2021 Apr; 19(4):413-417. PubMed ID: 32981388
[No Abstract] [Full Text] [Related]
8. Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.
Kumbhakar R; Neradilek M; Barnabas RV; Stewart J; Stankiewicz Karita HC; Landovitz RJ; Kissinger PJ; Jerome KR; Paasche-Orlow MK; Bershteyn A; Chu HY; Neuzil KM; Greninger AL; Luk A; Wald A; Brown ER; Johnston C
J Med Virol; 2022 Dec; 94(12):6091-6096. PubMed ID: 35940869
[TBL] [Abstract][Full Text] [Related]
9. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.
Ciorba A; Skarżyński PH; Pelucchi S; Hatzopoulos S
J Glob Antimicrob Resist; 2020 Dec; 23():263-264. PubMed ID: 33075521
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.
Cairoli E; Espinosa G
Med Clin (Barc); 2020 Aug; 155(3):134-135. PubMed ID: 32425245
[No Abstract] [Full Text] [Related]
11. Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
Perrella A; Orlando V; Trama U; Bernardi FF; Menditto E; Coscioni E
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696482
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
[No Abstract] [Full Text] [Related]
13. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
14. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):138-140. PubMed ID: 33080383
[No Abstract] [Full Text] [Related]
15. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
18. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
Chang R; Sun WZ
Drug Discov Today; 2020 Oct; 25(10):1786-1792. PubMed ID: 32629169
[TBL] [Abstract][Full Text] [Related]
19. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
Dhibar DP; Arora N; Kakkar A; Singla N; Mohindra R; Suri V; Bhalla A; Sharma N; Singh MP; Prakash A; Pvm L; Medhi B
Int J Antimicrob Agents; 2020 Dec; 56(6):106224. PubMed ID: 33166694
[TBL] [Abstract][Full Text] [Related]
20. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
